The trajectory of copyright's flagship drug presents a interesting case for investors in the pharmaceutical sector. While initially a phenomenal success, generating huge profits, the intellectual property expiration and the subsequent arrival of cheaper versions have significantly affected revenue. This presents questions about the future sustai… Read More